The number of registered unaffected BRCA1/2 carriers and the annual number of risk-reducing surgeries increased over time during the 22-year-long study period, reflecting an increased awareness of genetic predisposition for breast and ovarian cancer in both unaffected and affected women, as well as lowered costs of genetic testing [43]. Here, BRCA1 is linked to ovarian cancer.